We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-5.12%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$6.23B
AUM Growth
-$401M
Cap. Flow
+$712M
Cap. Flow %
11.42%
Top 10 Hldgs %
46.21%
Holding
101
New
19
Increased
9
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$193M
2
JBIO
Jade Biosciences
JBIO
+$189M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$104M
4
LENZ
LENZ Therapeutics
LENZ
+$67.1M
5
CNTB
Connect Biopharma Holdings
CNTB
+$66.7M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$92.3M
2
NVAX icon
Novavax
NVAX
+$81M
3
IGMS
IGM Biosciences
IGMS
+$75.4M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$52.4M
5
TGTX icon
TG Therapeutics
TGTX
+$50.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0.5%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.76M
$36.8M 0.59%
118,916
– –
INZY
52
DELISTED
Inozyme Pharma
INZY
$34.1M 0.55%
2,003,653
– –
VRNA
53
DELISTED
Verona Pharma
VRNA
$33.4M 0.54%
5,100,000
– –
BDTX icon
54
Black Diamond Therapeutics
BDTX
$113M
$31.6M 0.51%
2,589,904
– –
AKUS
55
DELISTED
Akouos Inc
AKUS
$28.6M 0.46%
2,281,249
– –
CNTA
56
DELISTED
Centessa Pharmaceuticals
CNTA
$28.4M 0.46%
+1,280,300
New +$30.1M
IPSC icon
57
Century Therapeutics
IPSC
$359M
$26.8M 0.43%
+914,094
New +$23.2M
NAUT icon
58
Nautilus Biotechnolgy
NAUT
$113M
$25M 0.4%
2,471,430
+1,500,000
+154% +$16.2M
CTMX icon
59
CytomX Therapeutics
CTMX
$586M
$22.2M 0.36%
3,500,000
– –
SCPH
60
DELISTED
scPharmaceuticals
SCPH
$16.7M 0.27%
2,731,170
– –
LRMR icon
61
Larimar Therapeutics
LRMR
$406M
$14.9M 0.24%
1,515,151
– –
TNGX icon
62
Tango Therapeutics
TNGX
$4.03B
$14.2M 0.23%
1,250,000
– –
ENTX icon
63
Entera Bio
ENTX
$495M
$14.1M 0.23%
+2,353,000
New +$8.7M
BLSA
64
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$13.2M 0.21%
1,250,000
– –
CNCE
65
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$12.8M 0.21%
3,033,603
– –
ATXS
66
DELISTED
Astria Therapeutics
ATXS
$12.6M 0.2%
+991,310
New +$12.9M
MIST icon
67
Milestone Pharmaceuticals
MIST
$115M
$12.4M 0.2%
2,246,503
– –
PNT
68
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$11.3M 0.18%
+1,098,318
New +$11.2M
EYPT icon
69
EyePoint Inc
EYPT
$316M
$11.2M 0.18%
1,250,000
– –
ARYD
70
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$10.7M 0.17%
1,000,000
– –
OCUL icon
71
Ocular Therapeutix
OCUL
$2.24B
$10.6M 0.17%
750,000
– –
PHAS
72
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$10.6M 0.17%
2,850,000
– –
IMA
73
ImageneBio Inc
IMA
$55.8M
$10.5M 0.17%
62,500
– –
ORIC icon
74
Oric Pharmaceuticals
ORIC
$1.28B
$10.3M 0.17%
584,000
– –
FLACU
75
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$10.1M 0.16%
1,000,000
– –
1 2
3
4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, RA Capital Management held 101 positions worth $6.23B, down 6.1% from $6.63B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $712M of net new capital in Q2 2021, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was Janux Therapeutics: 8,670,644 shares worth $216M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $81M trimmed.

  • RA Capital Management's largest Q2 2021 buy was Janux Therapeutics: 8,670,644 shares worth $216M.
  • RA Capital Management added most to Connect Biopharma Holdings in Q2 2021, an estimated $66.7M increase.
  • RA Capital Management's biggest Q2 2021 reduction was Novavax, cutting an estimated $81M.
  • RA Capital Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $92.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $6.23B portfolio in Q2 2021.
  • RA Capital Management opened 19 new positions and closed 9 in Q2 2021.
  • RA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $6.23B.

Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.